Clinical Trials Logo

Cancer Cachexia clinical trials

View clinical trials related to Cancer Cachexia.

Filter by:

NCT ID: NCT01238107 Completed - Cancer Cachexia Clinical Trials

A Clinical Study With MT-102 in Subjects With Cancer Cachexia

Start date: April 2011
Phase: Phase 2
Study type: Interventional

A phase II clinical study to evaluate MT-102 administered over a sixteen week period in subjects with cachexia related to non-small cell lung cancer and colorectal cancer

NCT ID: NCT00919659 Completed - Pancreatic Cancer Clinical Trials

Parenteral Nutrition Support for Patients With Pancreatic Cancer

Start date: January 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the additional nutrition support is improving the nutritional status of patients suffering cancer caxechia or not.

NCT ID: NCT00815685 Completed - Cancer Cachexia Clinical Trials

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

Start date: July 2007
Phase: N/A
Study type: Interventional

The data collected through this pilot study will allow us to increase our understanding of cancer cachexia and the effect of Eicosapentaenoic Acid (EPA) on cancer cachexia. Our long-term goal is to improve nutritional treatment and reduce illness in the cancer patient population.

NCT ID: NCT00378131 Completed - Cancer Cachexia Clinical Trials

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

Start date: September 2006
Phase: Phase 2
Study type: Interventional

Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and cachexia. This placebo controlled study will evaluate the safety and efficacy of RC-1291 HCl in cancer patients with cachexia.

NCT ID: NCT00329615 Completed - Cancer Cachexia Clinical Trials

Insulin Treatment in Cancer Cachexia

Start date: January 2000
Phase: Phase 4
Study type: Interventional

The study is designed to evaluate whether daily insulin treatment to weight losing cancer patients attenuates progression of cancer cachexia and improves metabolism.

NCT ID: NCT00267358 Completed - Cancer Cachexia Clinical Trials

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

Start date: November 2005
Phase: Phase 2
Study type: Interventional

Anorexia and cachexia are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and cachexia. This placebo controlled study will evaluate the safety and efficacy of RC-1291 HCl in cancer patients with anorexia and cachexia.

NCT ID: NCT00219817 Completed - Cancer Cachexia Clinical Trials

Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

Start date: June 2005
Phase: Phase 2
Study type: Interventional

Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.

NCT ID: NCT00094562 Completed - Cancer Clinical Trials

A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss

Start date: June 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of fish oil supplements in maintaining weight in people with disease-related weight loss and/or cachexia.